University of Toronto
3359 Mississauga Road N.
218 articles with University of Toronto
Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications
Sansero Life Sciences , a leader in the development of psilocybin-based medicines, announced today that it has partnered with the University of Toronto to complete a preclinical study on the effects of low-dose psilocybin. The study will bring new scientific understanding to psilocybin metabolism in the mammalian body and
Researchers at the University of Toronto have identified a protein called Importin-11 that transports beta-catenin into the nucleus of colon cancer cells, where it drives cell proliferation.
Absolute Antibody Partners with the Recombinant Antibody Network to Facilitate Access to Engineered Recombinant Antibodies
200+ recombinant antibodies to be engineered into new formats to advance research
Next generation liquid biopsy platform to revolutionize companion diagnostics
A team of researchers from the University of Toronto has combined CRISPR-based gene-editing technology with small biomagnetic devices to sort large populations of mixed cell types.
University of Toronto and Amgen Foundation Welcome Canadian Students to Prestigious Amgen Scholars Program
For the first time, Amgen Foundation grant offers Canadian undergraduate students the opportunity to gain hands-on research experience with world-leading U of T researchers
Developing egg cells conduct tests to select the healthiest of their energy-making machines to be passed to the next generation.
St. Baldrick's Robert J. Arceci Innovation Award provides scientists opportunity to pursue unrestricted research
IMS Web Viewer™ Selected for ER Simulator Exam Study
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Research Roundup: Gene Therapy for Deafness, Autism Genes, Breakthroughs in Parkinson’s and ALS, ...
3/1/2019There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Boehringer Ingelheim and Eli Lilly released data from their Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III trial in type 1 diabetes.
CCAB And Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates
The agreement provides Triumvira with an exclusive license for antibodies discovered at the U of T on specified therapeutic targets.
Medicine by Design and Creative Destruction Lab partner to accelerate the commercialization of world-class research in regenerative medicine
A new partnership between Medicine by Design and the Creative Destruction Lab (CDL) will strengthen Toronto's biomedical ecosystem by bringing together the University of Toronto's (U of T) world-class research in regenerative medicine and the CDL's proven seed-stage program for science-based companies.
New Nuclear Magnetic Resonance Technique Offers 'Molecular Window' Into Living Organisms, University of Toronto Study
Novel Femur Window Chamber Model For Long-Term Optical Access To Bone Marrow Compartment, University of Toronto Study
"Smart" Nanoparticle Called Pearls A Promising Gem To Target, Treat Tumors, University of Toronto Study